Searched for
BIOCON BIOSIMILARS BUSINESS
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...
- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Biocon betting big on new product launches for growthBiocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrate...
- Biocon Biologics to raise debt of Rs 4,500 crore for Viatris PayoutBiocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- On track to integrate major part of Viatris'' acquired biosimilars biz this fiscal: Kiran Mazumdar-ShawBiocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, accordin...
- 'Biocon Biologics to integrate Viatris' US biosimilar business by Q2 end'Biocon Biologics plans to complete the integration of Viatris' biosimilar business in North America by the end of Q2FY24, which is ahead of...
- Biocon Q1 Results: Profit drops 30% YoY to Rs 101 crore, revenue jumps 59%The company attributed the drop in net profit to depreciation, amortisation and interest increase of Rs 353 crore over last year primarily ...
- Biocon Biologics takes over Viatris' biosimilar biz in over 70 countriesBiocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countr...
- Kotak fund invests Rs 1070 crore in BioconEshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acqui...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
Load More
